Bain Capital Private Equity has agreed to acquire DSM Sinochem Pharmaceuticals (DSP), the global leader in sustainable antibiotics, next-generation statins and anti-fungals. DSP is a 50/50 joint venture of Heerlen-based DSM and Sinochem of Beijing. DSM said it was paid about €250m for its stake in the group. In 2017, DSP generated sales of approximately €440m. It has manufacturing sites and sales offices in China, India, the Netherlands, Spain, the US and Mexico, with approximately 2,000 employees. ‘DSM and Sinochem have been great supporters of our vision to be the global leader in generic pharmaceuticals,’ said Karl Rotthier, who heads DSP. ‘Bain Capital is now the ideal partner to drive DSP into its next stage of global development, given its deep healthcare expertise and operational skills across its worldwide team,’ he said.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to elena.di@visiongain.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.